Cure8 research brief
If you had biologic treatment before bowel surgery, this study suggests restarting the same class of biologic after ileocolonic resection may prevent postoperative recurrence as well as switching to a new class — and may be especially helpful for first-time resections or after prior anti-TNF exposure.
Adults with Crohn’s disease who have had or will have ileocolonic resection; patients previously treated with biologics (especially anti-TNF agents); gastroenterologists and colorectal surgeons.
This study looked at adults with Crohn’s disease who had ileocolonic resection (ICR) and had been exposed to biologic drugs before surgery.
Researchers compared three postoperative strategies started within 3 months of surgery: no biologic prophylaxis, reusing the same class of biologic the patient had before surgery (reutilization), or starting a new class of biologic.
On adjusted analysis, not giving a biologic was linked with a higher risk of composite postoperative recurrence (endoscopic and/or radiographic). Reutilization performed at least as well as starting a new class overall and showed longer recurrence-free survival for patients having their first ICR and for those previously exposed only to anti–TNF drugs.
How this was measured and what it means The paper used a composite outcome including endoscopic recurrence (Rutgeerts ≥ i2b) and radiographic recurrence and followed patients after surgery.
The finding supports that reusing the same biologic class after ICR can be a reasonable preventative approach in patients already exposed to biologics, but individual decisions depend on prior drug response and other clinical factors. Practical tone This is not treatment advice.
Talk with your gastroenterologist or surgeon about the pros and cons of restarting the same biologic class versus switching class after surgery, especially if this is your first bowel resection or if you were only exposed previously to anti-TNF agents.
Structured content depth: abstract — the classification and brief are based on the article abstract provided by the journal. The study is observational (retrospective cohort) and reports associations, not randomized comparisons. Individual treatment decisions should consider prior drug response, tolerability, and other patient-specific risk factors.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Perianal fistulizing Crohn's disease is difficult to treat and many patients have failed anti-TNF therapy. Evidence that ustekinumab achieves high clinical fistula response and remission rates in a real-world multicenter...
Perianal fistulizing Crohn's disease is a disabling complication; a subcutaneous form of infliximab could lower treatment burden and expand options if its effectiveness and safety in this specific setting are confirmed.
New clinical results for TREMFYA in perianal fistulizing Crohn's disease and positive data for another J&J IBD drug could signal future treatment options or regulatory milestones that matter to people with Crohn's and...
